DermTech reports Q2 EPS (99c), consensus (97c)

Reports Q2 revenue $3.98M, consensus $3.69M. “We’ve recently taken a few necessary steps to streamline operations and put all our energy into scaling the DermTech Melanoma Test and prioritizing reimbursed billable samples to grow revenue,” said Bret Christensen, CEO, DermTech. “We’re pursuing a large addressable market where significant patient need exists, with approximately 200,000 new cases of melanoma reported every year in the U.S. resulting in $3.3 billion in annual treatment costs. My vision is for the DMT to be deployed universally as part of the melanoma care pathway and we have an excellent product to execute against this goal.”